drug

Lialda ER

Marketedupdated 2mo ago

by Takeda Pharmaceuticals USA Inc

Approved

community read0 votes

indications

investigational

IBD (Crohn's + UC)

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Jul 24, 2027

~1.0 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

May 1, 2030method-of-use (U-1310)US 88656883.8y
Jun 6, 2028formulationUS 82170831.9y
Jun 6, 2028formulationUS 84360511.9y
Jul 24, 2027compositionUS 76458011.0y

Data sources

ClinicalTrials.gov

last refreshed just now

Found something off?

Trials studying Lialda ER

phase3A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitiswithdrawn
phase1Mesalamine 4 gm/60 mL Rectal Enemacompletedn=72
phase2Mesalazine Oral Suspension in Active Eosinophilic Esophagitiscompletedn=5